ArticleEcancermedicalscience2026
Epidemiological, clinical and therapeutic profile of hepatocellular carcinoma in Toamasina Madagascar.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: International recommendations for the management of hepatocellular carcinoma (HCC) are often difficult to apply in low-resource settings. This study aimed to describe the epidemiological, clinical, diagnostic and therapeutic characteristics of HCC patients managed at Analankininina University Hospital in Toamasina, Madagascar. Methods: This retrospective, descriptive cross-sectional study was conducted from January 1, 2017 to December 31, 2021. Diagnosis of HCC was based on histological confirmation or non-invasive radiological criteria (arterial enhancement with washout on dynamic imaging) and/or elevated alpha-fetoprotein >500 ng/ml in cirrhotic patients. Serological, radiological and therapeutic data were analysed. The Child-Pugh score was used to assess liver function and the Barcelona Clinic Liver Cancer (BCLC) classification was used for staging and therapeutic guidance. Alcoholism was defined as documented chronic excessive alcohol consumption recorded in medical files. Results: Forty-three patients were included. Mean age was 52.57 ± 19.74 years. The male-to-female ratio was 2.31. Most patients were diagnosed at advanced stages (BCLC C/D: 39/43). Alpha-fetoprotein was >500 ng/ml in 33/43 patients. Liver ultrasound was performed in all cases, CT scan in 9/43 and histological confirmation was obtained in 9/43. Symptomatic palliative care was administered in 33/43 patients. Conclusion: HCC is frequently diagnosed at an advanced stage in our setting, limiting curative treatment options. Limited access to dynamic imaging, histopathology and systemic therapies contributes to suboptimal management. Strengthening hepatitis B virus birth dose vaccination, early screening of at-risk populations and improving access to diagnostic tools are essential priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.